Clinical Trial Update: A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing DaTSCAN Ioflupane SPECT imaging for diagnosing Parkinsonian syndromes in Chinese patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease
• Parkinsonian Syndrome

Drugs mentioned

• DaTscan (ioflupane)

Snippet

Sponsor: GE Healthcare | Conditions: Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Status: COMPLETED | Results posted: 2023-10-16